SRPT - Sarepta Therapeutics - Stock & Dividends

Sarepta Therapeutics Inc is a biopharmaceutical company that specializes in developing innovative treatments for rare genetic diseases. The company's primary focus is on RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities that can help address the root causes of these debilitating conditions.

The company has already made significant strides in the treatment of Duchenne muscular dystrophy (DMD), a severe genetic disorder that affects muscle degeneration and weakness. Its flagship product, EXONDYS 51, is an injection that helps treat DMD in patients with a specific genetic mutation that can be addressed through exon 51 skipping. Similarly, VYONDYS 53 and AMONDYS 45 are designed to treat DMD in patients with different genetic mutations.

In addition to these treatments, Sarepta is also developing ELEVIDYS, a gene therapy that uses an adeno-associated virus to help treat ambulatory pediatric patients with DMD. This therapy has shown promising results in clinical trials and could potentially offer a new hope for young patients with this devastating disease.

The company's research pipeline is also filled with promising candidates, including SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA, and SRP-9003, a gene therapy program for limb-girdle muscular dystrophies. These programs demonstrate Sarepta's commitment to exploring new approaches to treating rare genetic diseases.

Sarepta has established a network of collaborations and license agreements with leading research institutions and biotech companies, including F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, and Genevant Sciences, among others. These partnerships enable the company to leverage cutting-edge technologies and expertise to accelerate the development of its therapies.

With a rich history dating back to 1980, Sarepta is headquartered in Cambridge, Massachusetts, and has established itself as a leader in the field of rare genetic disease treatment. For more information, visit the company's website at https://www.sarepta.com.